Back to search results

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Relapsed/Refractory Systemic Light Chain Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

  • Colorado Blood Cancer Institute/SCRI, Denver, Colorado, United States

  • Boston Medical Center, Boston, Massachusetts, United States

  • Karmanos Cancer Institute, Detroit, Michigan, United States

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

  • Ohio State University, Columbus, Ohio, United States

  • SCRI Oncology Partners, Nashville, Tennessee, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • National and Kapodistrian University of Athens, Athens, Greece

  • Seoul National University Hospital, Seoul, South Korea

  • Asan Medical Center, Seoul, South Korea

  • Samsung Medical Center, Seoul, South Korea

  • Seoul St. Mary's Hospital - The Catholic University of Korea, Seoul, South Korea

  • Hospital Universitari Son Espases, Palma, Balearic Islands, Spain

  • Clinica Universidad de Navarra - Pamplona, Pamplona, Navarre, Spain

  • Hospital de Cabuenes, Gijón, Principality of Asturias, Spain

  • Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

  • University Hospital La Fe, Valencia, Spain

  • University College London Hospitals, London, United Kingdom

  • The Christie NHS Foundation Trust, Manchester, United Kingdom

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)